MDS Podcast

Basic science research for movement disorder therapies is booming. Prof. Tiago Outeiro asks Dr. Lorraine Kalia what therapeutic targets she thinks are stealing the stage at this year's MDS Congress.

How can sleep predict cognitive decline in Parkinson's disease? Dr. Ron Postuma discusses his viewpoint and findings with Dr. Sarah Camargos at the MDS Congress.

MDS President Francisco Cardoso shares with Dr. Sara Schaefer his important takeaways from his presidential term and his hopes for the future.

What type of research is needed to help us better understand the phenomenology of stereotypic movements disroders? Dr. Hugo Morales asks Dr. Tammy Hedderly her viewpoint on the uniqueness of these disorders and what questions the field has yet to answer.

What direction will the field of PSP research go in the years to come? Prof. Gunter Höglinger sits down with Dr. Eduardo Fernandez at the MDS Congress to help answer that very question.

Multiple system atrophy (MSA) research has its challenges, nonetheless the field is still moving at a rapid pace. Dr. Eduardo Fernandez discusses the MDS Congress highlights for MSA with Dr. Alessandra Fanciulli.

Why is Parkinson's disease heterogeneity important to research. Dr. Connie Marras met with Dr. Eduardo Fernandez to discuss why understanding the heterogeneity of this disease may help with prevention.

What innovations in dystonia treatments do we have to look forward to? Dr. Mark Edwards sits down with Dr. Sarah Camargos to answer that vary question.

Dr. Sarah Camargos interviews Dr. Thiago Leal and Dr. Ignacio Mata about the need of genetic studies on underrepresented populations and the technical challenges they faced when alayzing admixture ancestries and X chromosome. Read the article

In this special issue celebrating the Movement Disorders journal Research Article of the Year 2023, Sara Schaefer discusses with Dr. Mario Zappia the effects of the short vs long duration responses to levodopa on cortical excitability and neuroplasticity in response to motor learning tasks in early Parkinson’s disease patients. Read the article »

In this special issue celebrating the Movement Disorders Clinical Practice journal Research Article of the Year 2023, Sara Schaefer discusses tic phenomenology in primary tic disorders vs. functional tic-like disorders with Dr. Tamara Pringsheim. Read the article »

Dr. Wszolek shares with Dr. Schaefer his extensive knowledge about the clinical, genetic, and pathological findings in Perry disease, a rare and likely underdiagnosed parkinsonian condition. Read the article.

In this episode, Dr. Pierre-Emmanuel Sugier discusses the epidemiological associations between PD and cancers. While investigating several European GWAS databases, his group raised the conundrum whether cancer and Parkinson's disease share common risk factors. Read the article.

In this episode, we interviewed Prof. Jian Feng about his most recent paper covering the role of parkin mutations in human A9 dopaminergic neurons and role they play in locomotor activities of early-onset PD. Journal CME is available until July 20, 2024 Read the article.

In this episode, Michele Matarazzo highlights the relevance of our society for the field and its members, with special guest Njideka Okubadejo.

In this episode Dr. Tiago Outeiro talks with Dr. Andrew Siderowf about the exciting new results in his most recent publication on alpha-synuclein seed amplification assay. Read the article.

Dr. Michele Matarazzo interviews Dr. Talene Yacoubian on an article recently published on the Movement disorders journal that reveals increased inflammatory markers in recently diagnosed patients with Parkinson's disease without medication, suggesting the important role of inflammation from the early stages of the disease. Furthermore, inflammatory biomarkers are related to cognition. Journal CME...

Dr. Christelle Nilles talks with Dr. Hugo Morales Briceno about the clinical presentations of Wilson’s disease patients with onset after 40 years and the challenges of diagnosing patients with atypical neurological manifestations. Read the article.

Sara Schaefer discusses the history, inner workings, and vision of the International Parkinson and Movement Disorder Society with current MDS President Francisco Cardoso.

Deep brain stimulation (DBS) has long been considered a risky procedure for people with Parkinson's disease and cognitive impairment. In this interview, Dr. Miocinovic presents real-world data, showing that DBS might be safe and useful in carefully selected patients with moderate cognitive impairment. Read the article.

In this History of Movement Disorders Special Episode, Prof. Tiago Outeiro interviews Prof. Maria Grazia Spillantini about integral work involved in discovering the role alpha-synuclein plays in the development of Lewy bodies. She discusses where the field is now and what questions young researchers should start asking.

In this special Hot Topics episode, Dr. Filip Scheperjans discusses what we know and what we don't yet know about the gut microbiome in Parkinson's disease, theories of influencing pathways within the gut-brain axis, and future directions for exploring and altering the gut microbiome in this patient population to impact disease.

Sara Schaefer discusses with Dr. Eduardo de Pablo-Fernandez his recent paper in Movement Disorders providing retrospective pathological validation of the 2022 MDS MSA Criteria using specimens from the Queens Square Brain Bank. Read the article.

In this paper, Dr. Vrustangkumar Shah and colleagues evaluated gait in patients with Parkinson's disease in the lab and in real life, with and without levodopa through wearable sensors. Some measures are able to discriminate fallers from non-fallers in PD. Read the article.

Two clinical trials with antibodies targeting alpha synuclein in early Parkinson's disease have been published in the New England Journal of Medicine. Anthony Lang and Gennaro Pagano, the first authors of the articles share the results and discuss the possible future perspectives with the MDS Podcast editor, Michele Matarazzo. Read the prasinezumab article. Read the cinpanemab article.